Zambon Pharma

What Zambon Pharma does

Zambon Pharma is a privately held, family-owned Italian pharmaceutical multinational founded in 1906 and headquartered in Bresso (Milan), with reported group revenue of 899 million euros and a workforce of approximately 2,768 employees across 15 countries. The company develops, manufactures, and commercializes branded pharmaceutical products in four primary therapeutic areas: severe respiratory diseases (Bronchiolitis Obliterans Syndrome, non-cystic fibrosis bronchiectasis, and cystic fibrosis via inhaled liposomal cyclosporine and Fluimucil/N-acetylcysteine), central nervous system disorders (Parkinson's disease through IPX203 licensed from Amneal, and ALS via the Aquestive partnership), pain management, and women's health (urinary tract infections). Its core technology spans sterile injectables, oral solids, lyophilized products, and liposomal inhalation formulations manufactured across four owned plants in Italy (Vicenza), Switzerland (Cadempino), China (Haikou), and Brazil (Barueri), supplemented by a Virtual Plant network coordinating 27 contract manufacturers globally.

The business operates a hybrid revenue model combining branded pharmaceutical sales (direct field sales forces targeting hospitals, specialists, and pharmacies across 87 countries), CDMO services for third-party pharmaceutical companies, and API/custom synthesis through the Zach System subsidiary. Distribution channels include direct enterprise sales, pharmacy distribution, hospital tenders, and B2B contract manufacturing relationships. Supporting the core pharma business, Zambon operates Zcube (a research venture running the Open Accelerator startup program), OpenZone (a scientific campus housing the new Z-LIFE headquarters), and Fondazione Zoé (health education). The company is led by Elena Zambon as President, with recent executive additions including a Chief Core Therapies Officer and Chief HR Officer in 2025, reflecting organizational alignment around therapeutic-area-focused growth and continued internationalization, particularly into China where Zambon secured regulatory approval and launched Fluimucil IV in June 2025.

Name

Zambon Pharma

Legal name

Zambon S.p.A.

Website

https://zambon.com

Company type

Private

Founded year

1906

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Zambon Pharma is a privately held, family-owned Italian pharmaceutical multinational founded in 1906 that develops and commercializes branded therapeutics in severe respiratory diseases, CNS disorders, pain, and women's health across 87 countries, with four manufacturing plants and a global CDMO business.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Small-Molecule API & Intermediates CDMO (HLAGABAA)

Keywords

• Pharmaceutical manufacturing
• Specialty therapeutics
• Contract development manufacturing
• Active pharmaceutical ingredients
• Respiratory disease treatment

Headquarters

HQ city

Milano

HQ country

Italy

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Products: Revenue from branded pharmaceutical products for severe respiratory diseases, respiratory diseases, pain, CNS disorders (Parkinson's, ALS), and women's health (urinary tract infections). Products include Fluimucil (N-acetylcysteine), treatments for cystic fibrosis, BOS, and NCFB.
2. CDMO Services: Contract manufacturing organization providing pharmaceutical development and manufacturing services to third-party pharmaceutical companies. Services span from formulation development through commercial production.
3. Active Pharmaceutical Ingredients (Zach System): Production and custom synthesis of Active Pharmaceutical Ingredients (API) and advanced intermediates for the pharmaceutical industry through Zach System division.
4. Virtual Plant / Toll Manufacturing: Management of outsourced production through network of 27 contract manufacturers globally, ensuring quality, supply continuity, and cost efficiency.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Zambon Pharma researches, develops, manufactures, and commercializes branded specialty pharmaceutical products across severe respiratory diseases (BOS, NCFB, cystic fibrosis), central nervous system disorders (Parkinson's disease, ALS), pain management, and women's health (urinary tract infections). The group also provides CDMO contract development and manufacturing services to third-party pharmaceutical companies, and through its Zach System division produces Active Pharmaceutical Ingredients and advanced intermediates. Core commercial products include Fluimucil (N-acetylcysteine), IPX203 (carbidopa/levodopa for Parkinson's), and inhaled liposomal cyclosporine for BOS.

Product overview

Zambon Pharma is a pharmaceutical multinational offering a diversified portfolio of therapeutic solutions across multiple specialty areas: severe respiratory diseases (BOS, NCFB, cystic fibrosis), neurological disorders (Parkinson's disease, ALS), pain management, and women's health (urinary tract infections). The core pharmaceutical business operates alongside supporting entities including Zach System (API manufacturing and custom synthesis), Zcube (digital health innovation and Open Accelerator program), and the OpenZone campus. Key products include Fluimucil (N-acetylcysteine respiratory therapy), IPX203 (Parkinson's carbidopa/levodopa formulation), and inhaled liposomal cyclosporine for BOS. The company also offers CDMO services through its manufacturing plants in Italy, Switzerland, China, and Brazil, plus a Virtual Plant network managing 27 contract manufacturers globally.

Differentiator

Problem solved

Functional benefit

Brands

• Z-Life: The new headquarters of Zambon Pharma, created within the OpenZone campus, designed to promote an approach based on sharing without borders and transforming ideas into tangible opportunities for patients.
• Benvivere
• Open Accelerator
• Zgen
• Zambon For Kids
• Zambon For Others
• Health & Quality Factory
• Fluimucil
• Zach System

Products and services

• Fluimucil (N-acetylcysteine) N-acetylcysteine-based therapeutic solution for respiratory conditions, available in multiple formulations including IV for severe cases, used to treat cough, cold, influenza, acute bronchitis, and COPD.
• IPX203 New oral formulation of carbidopa/levodopa for the treatment of Parkinson's disease, licensed exclusively from Amneal Pharmaceuticals for the EU, UK, and Switzerland markets.
• Inhaled Liposomal Cyclosporine Investigational formulation delivering elevated bronchiolar concentrations to halt progression of Bronchiolitis Obliterans Syndrome (BOS) following lung and hematopoietic stem cell transplantation.
• CDMO Contract Development and Manufacturing Services Contract Development and Manufacturing Organization services offering formulation studies, analytical method development and validation, clinical trial batches, scale-up, process validation, and stability studies. Capabilities span oral forms (tablets, coated tablets, granules, effervescent tablets, solutions, syrups, drops, ear drops, nasal sprays) and sterile forms (injectables, lyophilized products, vials, ampoules, sterile powder).
• Zach System API and Custom Synthesis Production and custom synthesis of Active Pharmaceutical Ingredients (API) and advanced intermediates for the pharmaceutical industry through the Zach System division, operated from an FDA-inspected multipurpose facility in Avrillé, France with reactors from 50L to 10,000L.

Quantifiable outcome

• 75% of lung transplant patients develop BOS within 10 years
• +4 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered minor and core.

• CultipharmminorStrategic or Co-development Partner · 28 April 2026Cultipharm and Zambon announced a strategic agreement for the development of new advanced nutraceutical product lines, expanding into the health supplements market.
• Chinese Regulatory Authorities (sFDA)coreOthers · 24 June 2025Zambon obtained regulatory approval from China's sFDA (State Food and Drug Administration) and launched Fluimucil IV (N-acetylcysteine intravenous formulation) in China following a clinical development program conducted entirely in the country. This represents a significant market entry milestone.
• Amneal PharmaceuticalscoreOEM/ Whitelabel/ Licensing Partner · 1 January 2024Zambon Biotech SA signed an exclusive license agreement with Amneal Pharmaceuticals for IPX203 - a new oral formulation of carbidopa/levodopa for Parkinson's disease treatment - covering European Union, United Kingdom, and Switzerland markets.
• AquestivecoreStrategic or Co-development Partner · 1 January 2019Collaboration with Aquestive for ALS (Amyotrophic Lateral Sclerosis) treatment formulation. Through this partnership, Zambon expanded its CNS portfolio with a new formulation that is now commercialized in some European countries, addressing orphan diseases and CNS therapeutic area.
• International Scientific CommunitycoreStrategic or Co-development PartnerZambon strengthens collaborations with the international scientific community and representative patient groups through participation in international congresses and publication of clinical data in important journals. Global Medical Office R&D works to build a proprietary product pipeline with global presence.
• Other Italian Pharmaceutical Companies in ChinaminorOthersItalian pharmaceutical companies including Chiesi, Bracco, and Recordati are mentioned as peers deepening strategic presence in China through local clinical trials, product launches, and manufacturing investments - context for competitive landscape rather than direct partnerships.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Chiesi Farmaceutici: Italian family-owned multinational pharmaceutical company with a strong respiratory focus (similar to Zambon's severe respiratory franchise) and comparable mid-size private scale. Operates globally with branded specialty pharma and CDMO operations, making it the closest direct analog to Zambon in therapeutic focus, ownership structure, and geographic reach.
• Menarini Group: Italian privately-held pharmaceutical group of similar scale and heritage, operating across specialty therapeutics with global commercialization. Comparable in family/private ownership, European HQ, multi-country manufacturing, and broad therapeutic area coverage including specialty and consumer health segments.
• Recordati: Italian specialty pharmaceutical company listed on the Milan Stock Exchange, focused on rare diseases, CNS, and specialty therapeutics. Comparable therapeutic mix (CNS/specialty) and Italian heritage; serves as a useful listed-comp valuation reference for Zambon's specialty pharma franchise.
• Angelini Industries: Italian privately-held diversified group with a significant pharmaceutical division (Angelini Pharma) operating across CNS, pain, and consumer health. Comparable in private family ownership, Italian heritage, mid-size European scale, and presence across similar therapeutic categories including pain and women's health.
• H. Lundbeck: Danish specialty pharmaceutical company with a CNS-focused franchise (similar to Zambon's Parkinson's and ALS investments). Comparable mid-cap specialty pharma profile with concentrated CNS therapeutic focus and similar revenue band.
• Ipsen: French specialty pharmaceutical company with strong CNS, oncology, and rare-disease franchises. Comparable mid-cap European specialty pharma profile with focus on high-unmet-need therapeutic areas, similar to Zambon's severe respiratory and CNS positioning.

Broad incumbents

• Almirall: Spanish listed specialty pharmaceutical company focused on dermatology and specialty therapeutics, with European-wide commercialization. Comparable in mid-cap specialty pharma scale and European geographic footprint, though more concentrated in dermatology rather than CNS/respiratory.
• UCB: Belgian specialty pharmaceutical company with a strong CNS franchise (epilepsy, Parkinson's) and immunology focus. Comparable in CNS therapeutic overlap (notably Parkinson's) and European specialty pharma positioning, though UCB is a substantially larger publicly-listed company.
• Catalent: Global CDMO serving the pharmaceutical industry across drug substance, drug product, and clinical supply. Comparable to Zambon's CDMO/Virtual Plant and Zach System API operations as a peer for benchmarking contract manufacturing scale, capabilities, and margins.

Emerging players

• Jazz Pharmaceuticals: Irish/US specialty pharmaceutical company with a CNS and rare-disease franchise (narcolepsy, epilepsy, oncology). Comparable in CNS specialty focus and rare-disease commercial model, though more US-centric and listed, providing a useful reference for Zambon's CNS commercialization economics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/zambon
• Instagraminstagram.com/zambon1906
• Xx.com/zambonpharma
• Facebookfacebook.com/105276846263025

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zambon Pharma